ACC 2024 | PREVENT Study

The use of intravascular imaging to identify vulnerable plaque (VP) has proven to be very useful, as such plaque is associated with an increase in major adverse cardiac events. Optimal medical treatment is currently considered the standard strategy to stabilize VP. However, the safety and effectiveness of preventive treatment with percutaneous coronary intervention (PCI) in VP are still unclear.

ACC 2024

The aim of this randomized controlled study was to evaluate whether preventive PCI of VP improves clinical outcomes compared with medical treatment alone.

The primary endpoint (PEP) was target-vessel failure (TVF), defined as a set of events including death from cardiac causes, myocardial infarction related to the treated vessel, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina after 2 years of randomization. VP lesions to be assessed were defined as coronary stenosis greater than 50% with negative coronary fraction flow reserve (FFR) (≥0.80) along with two of the following criteria: minimum luminal area (MLA) ≤4 mm2, plaque volume >70%, presence of thin-cap fibroatheroma identified through optical coherence tomography (OCT) or intravascular ultrasound (IVUS), and presence of lipid-rich plaque identified by near-infrared spectroscopy (NIRS).

Read also: ACC 2024 | DanGer-Shock Trial.

A total of 1600 patients were analyzed; 800 of them were randomized to the medical treatment alone group and 800 to the preventive PCI plus medical treatment group. Regarding the PFP, the preventive PCI plus medical treatment group had a lower cumulative incidence of TVF at 2 years compared with the medical treatment alone group (preventive PCI 0.4% vs. medical treatment 3.4%; hazard ratio [HR] 0.11 [95% confidence interval (CI) 0.03-0.36], p=0.0003). These results were sustained at 7 years of follow-up, with a lower incidence of TVF in the preventive PCI group (6.5%) compared with the medical treatment alone group (9.4%): HR 0.54 [95% CI 0.33-0.87], p=0.0097.

Conclusions

In conclusion, in this study, preventive PCI along with medical treatment resulted in a lower incidence of major adverse cardiac events compared with medical treatment alone in VP lesions that did not limit coronary flow.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: PREVENT Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques.

Reference: Seung-Jung Park et al. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...

New Balloon-Expandable Aortic Valve: 30-Day Outcomes in Patients with Small Aortic Annulus

As transcatheter aortic valve implantation (TAVI) continues to expand toward younger patients with longer life expectancy, factors such as valve hemodynamic performance, durability, and...